Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Galapagos AEX:GLPG.NL, BE0003818359

  • 32,300 1 mrt 2024 17:38
  • -0,590 (-1,79%) Dagrange 32,130 - 32,680
  • 121.102 Gem. (3M) 84,9K

Galapagos april 2020

3.512 Posts
Pagina: «« 1 ... 164 165 166 167 168 ... 176 »» | Laatste | Omlaag ↓
  1. forum rang 8 closer 29 april 2020 19:05
    uit The Guardian (liveblog 18:26):

    No clinical benefits from remdesivir, study finds
    Treating coronavirus patients with the antiviral drug remdesivir showed no “significant clinical benefits” in the first randomised trial of its kind, according to research released on Wednesday, AFP reports.

    In a study among more than 200 Covid-19 patients in Wuhan, China, published in The Lancet, doctors found no positive effects of administering the drug compared with a control group of adults.

    The findings were released after US pharmaceutical giant Gilead, which makes remdesivir, said a separate large-scale trial with the drug had showed positive results.

    “Unfortunately, our trial found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo,” said Bin Cao from China-Japan Friendship Hospital and Capital Medical University in China, who led the research.

    “This is not the outcome we hoped for.”
  2. durobinet 29 april 2020 19:08
    quote:

    closer schreef op 29 april 2020 19:05:

    uit The Guardian (liveblog 18:26):

    No clinical benefits from remdesivir, study finds
    Treating coronavirus patients with the antiviral drug remdesivir showed no “significant clinical benefits” in the first randomised trial of its kind, according to research released on Wednesday, AFP reports.

    In a study among more than 200 Covid-19 patients in Wuhan, China, published in The Lancet, doctors found no positive effects of administering the drug compared with a control group of adults.

    The findings were released after US pharmaceutical giant Gilead, which makes remdesivir, said a separate large-scale trial with the drug had showed positive results.

    “Unfortunately, our trial found that while safe and adequately tolerated, remdesivir did not provide significant benefits over placebo,” said Bin Cao from China-Japan Friendship Hospital and Capital Medical University in China, who led the research.

    “This is not the outcome we hoped for.”
    Tja, kennelijk China tegen Amerika!?

    Fauci gives his blessing to remdesivir
    Apr. 29, 2020 12:22 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Stephen Alpher, SA News Editor
    The result from Gilead's (NASDAQ:GILD) trial of remdesivir is "quite good news," says "President" Anthony Fauci, with the data showing "clear cut significant positive effect in diminishing the time to recovery." The FDA, he says, is working with Gilead on the availability of the drug.

    The Chinese study (negative results leaked last week, and details published this morning) was "underpowered, not adequate," says Fauci.

    Fauci's comments seem to have put an extra charge into GILD - shares are now up 7% for the session.
3.512 Posts
Pagina: «« 1 ... 164 165 166 167 168 ... 176 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Galapagos Meer »

Koers 32,300   Verschil -0,59 (-1,79%)
Laag 32,130   Volume 121.102
Hoog 32,680   Gem. Volume 84.886
1 mrt 2024 17:38
Premium

Weinig houvast voor beleggers in Galapagos

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Gerelateerde Video's

  1. video thumbnail

    Galapagos gaat als de brandweer

    31 maart 2017 14:21 - Vimeo

  2. video thumbnail

    Arend Jan Kamp over hoofdkantoren

    7 februari 2017 16:38 - Vimeo

  3. video thumbnail

    Arend Jan Kamp over biotech

    2 februari 2017 16:33 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Galapagos

    9 juni 2016 16:08 - Vimeo

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links